Information Provided By:
Fly News Breaks for January 16, 2020
Jan 16, 2020 | 11:26 EDT
Baird analyst Madhu Kumar downgraded Neon Therapeutics to Neutral from Outperform with a price target of $2, down from $15.00. BioNTech (BNTX) and Neon Therapeutics announced earlier that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67M.